Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.
Por:
Garcia-Gea, C, Martinez, J, Ballester, MR, Gich, I, Valiente, R, Antonijoan, RM
Publicada:
1 mar 2014
Resumen:
ObjectiveThe aim of this study was to compare the effects of concomitant administration of alcohol and bilastine versus alcohol alone on the central nervous system.
MethodsTwenty-four healthy young volunteers of both sexes participated in a randomized, double-blind, double-dummy, crossover, and positive-controlled and placebo-controlled clinical trials. At 1-week intervals, subjects received six different treatments: (i) placebo; (ii) alcohol 0.8g/kg alone (ALC); (iii) ALC in combination with: bilastine 20mg (B20+A); (iv) bilastine 80mg (B80+A); (v) cetirizine 10mg (CET+A); and (vi) hydroxyzine 25mg (HYD+A). Psychomotor performance tests (fine motor, finger tapping, nystagmus, critical flicker-fusion frequency, temporal estimation, d2' cancellation, and simple reaction time) and subjective self-reports (drunkenness, drowsiness, mental slowness, clumsiness, anger, attentiveness, competence, happiness, hostility, interest, and extroversion) were carried out at baseline and multiple points thereafter.
ResultsAll active treatments induced a significant psychomotor impairment. The greatest and most lasting impairment was observed with HYD+A followed by B80+A and CET+A. In contrast, objective measures showed less impairment with B20+A and ALC, both with a similar magnitude. Self-reports showed a subjective perception of performance impairment in all active treatments.
ConclusionConcomitant administration of bilastine (at therapeutic dose) and alcohol does not produce greater central nervous system depressant effects than ACL alone. Copyright (c) 2014 John Wiley & Sons, Ltd.
Filiaciones:
Garcia-Gea, C:
Hosp Santa Creu & Sant Pau, CIM, IIB, IR,Serv Farmacol Clin, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
Martinez, J:
Hosp Santa Creu & Sant Pau, CIM, IIB, IR,Serv Farmacol Clin, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
Ballester, MR:
Hosp Santa Creu & Sant Pau, CIM, IIB, IR,Serv Farmacol Clin, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain
Gich, I:
Hosp Santa Creu & Sant Pau, CIM, IIB, IR,Serv Farmacol Clin, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain
Serv Epidemiol Clin, Barcelona, Spain
Valiente, R:
FAES FARMA SA, Dept Clin Invest, Vizcaya, Spain
Antonijoan, RM:
Hosp Santa Creu & Sant Pau, CIM, IIB, IR,Serv Farmacol Clin, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
CIBERSAM, Ctr Invest Biomed Red Salud Mental, Madrid, Spain
|